Detection chip for tumor driving gene and application thereof

Abstract

The invention discloses a detection chip for a tumor driving gene and application thereof. The detection chip for the tumor driving gene comprises an ALK (anaplastic lymphoma kinase) fusion detection agent, an EGFR (epidermal growth factor receptor) fusion detection agent, an RET (reticulocyte) fusion detection agent and an ROS1 (reactive oxygen species 1) fusion detection agent. Proofed by the results of clinical detect, after fusion probes corresponding to the ALK, the EGFR, the RET and the ROS1 are specifically designed, the detection chip has the advantages that the sensitivity is high, and the gene fusion between a particular site area of the ALK, the EGFR, the RET and the ROS1 and fusion segments is specifically detected. The invention further discloses a detection chip for detecting a second sequence group of the gene mutation and a third sequence group of the gene amplification; after detecting once, the gene fusion, gene mutation and gene amplification of the multiple tumor driving genes, such as the ALK, BRAF (aserine / theroninespecific kinases), DDR2 (discordin domain receptor 2), the EGFR, ERBB2 (receptor tyrosine kinase 2), FGFR1 (fibroblast growth factor receptor 1), KRAS (kirstenrat sarcoma viral oncogene), MET (methionine), NRAS, PIK3CA (phosphatidylino-sitol 3-kinases), the RET and the ROS1.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a tumor driver gene detection chip and its application. Background technique [0002] Tumors are a group of malignant diseases caused by driver genes, which are characterized by high morbidity and high mortality. Common tumor driver genes include ALK gene, BRAF gene, DDR2 gene, EGFR gene, ERBB2 gene, FGFR1 gene, KRAS gene, MET gene, NRAS gene, PIK3CA gene, RET gene and ROS1 gene, etc. In the past 10 years, the incidence of tumors in my country has increased rapidly, seriously endangering public health. Clinical studies have found that about 87% of patients have known driver genes, of which about 81% of driver genes have clear targeted inhibitors, and 66% of patients can receive individualized targeted therapy with marketed drugs. The results of the study showed that by detecting the driver gene and receiving targeted therapy, the patient's survival time can be extended by at least ...

AI Technical Summary

Problems solved by technology

Traditional detection products have low sensitivity and are generally only designed for the mutation or amplification of tumor driver genes, but it is difficult to detect whether a tumor driver gene is fused with a fusion fragment

Images